Abstract
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
William J Shergy, Reuben A Isern, David A Cooley, John L Harshbarger, J Eugene Huffstutter, Gordon M Hughes, Elizabeth A Spencer-Smith, Allan L Goldman, Sanford H Roth, J Scott Toder, Diana Warner, Adrienne Quinn, Gregory F Keenan, Thomas F Schaible and PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial
The Journal of Rheumatology April 2002, 29 (4) 667-677;
William J Shergy
Reuben A Isern
David A Cooley
John L Harshbarger
J Eugene Huffstutter
Gordon M Hughes
Elizabeth A Spencer-Smith
Allan L Goldman
Sanford H Roth
J Scott Toder
Diana Warner
Adrienne Quinn
Gregory F Keenan
In this issue
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
William J Shergy, Reuben A Isern, David A Cooley, John L Harshbarger, J Eugene Huffstutter, Gordon M Hughes, Elizabeth A Spencer-Smith, Allan L Goldman, Sanford H Roth, J Scott Toder, Diana Warner, Adrienne Quinn, Gregory F Keenan, Thomas F Schaible, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial
The Journal of Rheumatology Apr 2002, 29 (4) 667-677;
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
William J Shergy, Reuben A Isern, David A Cooley, John L Harshbarger, J Eugene Huffstutter, Gordon M Hughes, Elizabeth A Spencer-Smith, Allan L Goldman, Sanford H Roth, J Scott Toder, Diana Warner, Adrienne Quinn, Gregory F Keenan, Thomas F Schaible, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial
The Journal of Rheumatology Apr 2002, 29 (4) 667-677;